HOME >> BIOLOGY >> NEWS
Rare but deadly heart disease is curable, study shows

Fatigue, fever and muscle aches -- classic symptoms of flu -- are for a small number of patients symptoms of a very rare but deadly form of heart disease.

The condition, fulminant myocarditis, is underdiagnosed. The good news, according to a study led by Johns Hopkins researchers, is that patients who are properly diagnosed and treated aggressively can fully recover from the condition within two weeks without much damage to the heart or chance of relapse.

Results are reported in the March 9 issue of the New England Journal of Medicine.

"This illness has a very rapid progression and the consequences are very dramatic -- patients can die suddenly," says Joshua M. Hare, M.D., associate director of the heart failure and cardiac transplant program at Hopkins and an author of the study. "We want to make physicians aware that although this condition is uncommon, it should be considered in patients with flu-like symptoms and fluid in the lungs. An echocardiogram suggests the disease, and a heart tissue biopsy confirms the diagnosis."

Fulminant myocarditis is a severe inflammation of the muscular wall of the heart, usually caused by a viral or other infection, or an immune disorder. It comes on suddenly, leaving the heart virtually powerless to contract and circulate blood. The condition is so rare that it affects less than one in a million patients, yet in those people it often proves fatal.

Effective treatments include medications to stimulate the heart muscle, thereby increasing blood flow, or an implantable mechanical pump to temporarily assist the heart with circulation, Hare says. Pumps can usually be removed safely after seven to 10 days.

"Physicians should use any means necessary to maintain these patients' heart function, as virtually all will recover within two weeks and then lead a normal life," says Kenneth L. Baughman, M.D., senior author of the study and director of the Division of Cardiology at Hopkins.

Patie
'"/>

Contact: Karen Infeld
kinfeld@jhmi.edu
410-955-1534
Johns Hopkins Medical Institutions
8-Mar-2000


Page: 1 2

Related biology news :

1. Missing genes may help explain why plague bacteria are so deadly
2. $18 million bioinformatics center to become weapon against deadly diseases
3. UC Irvine scientists to develop vaccine to combat bioterrorism threat from deadly bacteria
4. Stanford researchers findings may shed light on common, deadly birth defect
5. Crop rotation may help wait out soil pathogen deadly to pumpkins
6. New tumor suppressor may play important role in deadly brain tumors
7. Failure of DNA repair mechanism precedes final stage of deadly leukemia, new Penn study shows
8. Drugs limit deadly side effects of graft-versus-host disease
9. Approved drug blocks deadly anthrax toxin
10. Researchers determine reason for deadly spread of 1918 influenza
11. Scientists discover how anthrax creates its deadly spores

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/8/2016)... , March 8, 2016   Valencell ... technology, today announced it has secured $11M in ... GII Tech, a new venture fund being launched ... additional participation from existing investors TDF Ventures and ... funds to continue its triple-digit growth and accelerate ...
(Date:3/3/2016)... MONTEREY, Calif. , March 3, 2016 /PRNewswire/ ... Partner, launched this week highlighting advancements in flexible, ... – a record setting attendance - have gathered ... in this fast-growing field of electronics. The Flex ... a focal point for companies, R&D organizations, and ...
(Date:3/2/2016)... March 2, 2016 ... addition of the  "Global Biometrics Market in ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , Global biometrics ... at a CAGR of around 27%   ... has announced the addition of the  "Global ...
Breaking Biology News(10 mins):
(Date:5/4/2016)... N.J. , May 4, 2016  Bayer ... its oncology compound Stivarga ® (regorafenib) tablets ... carcinoma (HCC) has met its primary endpoint of ... study, called RESORCE, evaluated the efficacy and safety ... has progressed after treatment with sorafenib. The safety ...
(Date:5/4/2016)... New York, NY (PRWEB) , ... May 04, ... ... growth, has leveraged recent innovations in biotechnology to help treat hormonal and stress ... hair loss, Nutrafol® has captured the hearts of key opinion leaders in the ...
(Date:5/3/2016)... ... 03, 2016 , ... Leading CEOs from biotech, pharmaceutical, and ... June 1st at The Four Seasons Hotel Boston. , The Boston CEO Conference ... exclusive access to key decision makers who influence deal making and investment. Attendees ...
(Date:5/3/2016)... -- - And Other Rising Companies - ... Competitor Biologics  - Biosimilar Drug Producers - ... Who are the most important and promising ... sales potentials? Discover, in our updated survey, organisations, outlooks ... revenue forecasting. Visiongain,s new study ...
Breaking Biology Technology:
Cached News: